RxDoctor Payments Data

Nadine Nguyen

Adult Health · Orlando, FLNPI 1104165802

Payments from drug & device makers

$2,868in general payments, 2019–2025

Across 91 payments — averaging $31.52 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Medtronic$1K
  • Endo USA, Inc.$225
  • Teleflex LLC$168
  • Neurocrine Biosciences, Inc.$125
  • Astellas Pharma US Inc$100
  • Abiomed$96
  • plus $822 from 20 others

What the payments were for

  • Travel & lodging$83729%
  • Food & beverage$1,90566%
  • Education$1274%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,868 in reported general payments places this provider in the 80th percentile of 2,237 adult health providers in Florida.

See all adult health providers in Florida

Medicare billing

Part B allowed, 2024
$93,643
Medicare patients
461
Services billed
1,858

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
GemtesaVibegron165$126,031
MyrbetriqMirabegron14$10,254
Alfuzosin Hcl ErAlfuzosin Hcl328$5,891
Potassium Citrate ErPotassium Citrate50$3,971
Trimethoprim47$3,264
Solifenacin Succinate115$3,048
Testosterone20$2,959
Tamsulosin Hcl180$2,259
Nitrofurantoin Mono-MacroNitrofurantoin Monohyd/M-Cryst60$1,968
Cephalexin157$1,570
NitrofurantoinNitrofurantoin Macrocrystal26$1,077
Estradiol15$729
Levofloxacin150$604
Clobetasol Propionate14$594
Cefdinir20$295

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Sumitomo Pharma America, Inc.Gemtesa$95$126,031165 claims
Astellas Pharma US IncMyrbetriq$100$10,25414 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 2,237 adult health providers in Florida.

Other adult health in Orlando

See the full list for Florida

Where these figures come from

Is this you, or does something look wrong? →